<p>Opthea Limited 未赞助的 ADR (NASDAQ:OPT - 获取免费报告) 股价在周五上涨了 7.2%。该公司股价最高达到 $3.48，最后交易价为 $3.41。在午盘交易中，交易了 3,000 股。该股票之前收盘价为 $3.18。</p>
<h2>分析师评级变动</h2>
<ul>
<li>如何投资可再生能源</li>
</ul>
<p>另外，Weiss Ratings 在 10 月 14 日的报告中重申了对 Opthea 股票的 &#34;卖出 (d-)&#34; 评级。一位研究分析师给予该股票 &#34;强烈买入&#34; 评级，四位分析师给予 &#34;持有&#34; 评级，另外两位分析师给予 &#34;卖出&#34; 评级。根据 MarketBeat.com 的数据，该公司的共识评级为 &#34;持有&#34;，共识目标价为 $1.33。</p>
<p><strong>查看我们对 OPT 的最新分析</strong></p>
<h2>Opthea 股价上涨 7.2%</h2>
<p>该公司的 50 日移动平均线为 $3.41，200 日移动平均线也为 $3.41。</p>
<h2>机构投资者对 Opthea 的看法</h2>
<p>大型投资者最近对该公司的持仓进行了调整。EP Wealth Advisors LLC 在第一季度购买了 Opthea 的新股份，价值约 $34,000。OLD Mission Capital LLC 在第一季度将其在 Opthea 的持仓增加了 78.7%。OLD Mission Capital LLC 现在拥有 19,167 股该公司的股票，价值 $65,000，此前在该期间又购买了 8,439 股。Twin Lakes Capital Management LLC 在第一季度将其在 Opthea 的持仓增加了 67.4%。Twin Lakes Capital Management LLC 现在拥有 33,156 股该公司的股票，价值 $113,000，此前在该期间又购买了 13,350 股。最后，Regal Partners Ltd 在第一季度将其在 Opthea 的持仓增加了 78.6%。Regal Partners Ltd 现在拥有 5,193,688 股该公司的股票，价值 $17,710,000，此前在该期间又购买了 2,286,285 股。机构投资者持有该公司 55.95% 的股票。</p>
<h2>关于 Opthea</h2>
<p>(获取免费报告)</p>
<p>Opthea Limited 是一家临床阶段的生物制药公司，专注于在澳大利亚开发和商业化主要用于眼病的治疗。该公司的开发活动基于涵盖血管内皮生长因子 (VEGF) VEGF-C、VEGF-D 和 VEGF 受体-3 的知识产权组合，用于治疗与血管和淋巴管生长以及血管渗漏相关的疾病。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们更看好的股票比 Opthea 更好</li>
<li>如何购买黄金股票并投资黄金</li>
<li>Rayonier-PotlatchDeltic 合并预示行业上行</li>
<li>为什么这些公司被视为蓝筹股？</li>
<li>Hims &amp; Hers 空头头寸接近历史高点，是否应该买入？</li>
<li>如何计算期权利润</li>
<li>这只防御性股票有 $570 亿的订单积压和新的 AI 发展机遇</li>
</ul>
<p><em>此即时新闻提醒是由叙述科学技术和 MarketBeat 的金融数据生成的，旨在为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送邮件至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 $1,000 在 Opthea 吗？</h2>
<p>在你考虑 Opthea 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前买入……而 Opthea 并不在名单上。</p>
<p>虽然 Opthea 目前在分析师中获得了 &#34;持有&#34; 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

OPTEY

<p>Opthea Limited（纳斯达克代码：OPT）周五股价上涨 7.2%，至 3.41 美元，较前一交易日的 3.18 美元有所上升。分析师评级显示一项强烈买入、四项持有和两项卖出评级，市场共识目标价为 1.33 美元。机构投资者持有该股票的 55.95%，多家公司的持股显著增加。Opthea 专注于在澳大利亚开发眼病治疗方案，利用其在血管内皮生长因子（VEGF）方面的知识产权</p>

<p>Opthea Limited Unsponsored ADR (NASDAQ:OPT - Get Free Report) shares traded up 7.2% on Friday . The company traded as high as $3.48 and last traded at $3.41. 3,000 shares traded hands during mid-day trading, The stock had previously closed at $3.18.</p>
<div class="lb-trans"><p>Opthea Limited 未赞助的 ADR (NASDAQ:OPT - 获取免费报告) 股价在周五上涨了 7.2%。该公司股价最高达到 $3.48，最后交易价为 $3.41。在午盘交易中，交易了 3,000 股。该股票之前收盘价为 $3.18。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><ul>
<li>How to Invest in Renewable Energy</li>
</ul>
<div class="lb-trans"><ul>
<li>如何投资可再生能源</li>
</ul>
</div><p>Separately, Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of Opthea in a report on Tuesday, October 14th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of &#34;Hold&#34; and a consensus target price of $1.33.</p>
<div class="lb-trans"><p>另外，Weiss Ratings 在 10 月 14 日的报告中重申了对 Opthea 股票的 &#34;卖出 (d-)&#34; 评级。一位研究分析师给予该股票 &#34;强烈买入&#34; 评级，四位分析师给予 &#34;持有&#34; 评级，另外两位分析师给予 &#34;卖出&#34; 评级。根据 MarketBeat.com 的数据，该公司的共识评级为 &#34;持有&#34;，共识目标价为 $1.33。</p>
</div><p><strong>View Our Latest Analysis on OPT</strong></p>
<div class="lb-trans"><p><strong>查看我们对 OPT 的最新分析</strong></p>
</div><h2>Opthea Stock Up 7.2%</h2>
<div class="lb-trans"><h2>Opthea 股价上涨 7.2%</h2>
</div><p>The company has a 50 day moving average of $3.41 and a 200 day moving average of $3.41.</p>
<div class="lb-trans"><p>该公司的 50 日移动平均线为 $3.41，200 日移动平均线也为 $3.41。</p>
</div><h2>Institutional Investors Weigh In On Opthea</h2>
<div class="lb-trans"><h2>机构投资者对 Opthea 的看法</h2>
</div><p>Large investors have recently made changes to their positions in the company. EP Wealth Advisors LLC bought a new stake in shares of Opthea in the 1st quarter valued at approximately $34,000. OLD Mission Capital LLC boosted its position in Opthea by 78.7% during the first quarter. OLD Mission Capital LLC now owns 19,167 shares of the company's stock worth $65,000 after purchasing an additional 8,439 shares during the period. Twin Lakes Capital Management LLC boosted its position in Opthea by 67.4% during the first quarter. Twin Lakes Capital Management LLC now owns 33,156 shares of the company's stock worth $113,000 after purchasing an additional 13,350 shares during the period. Finally, Regal Partners Ltd boosted its position in Opthea by 78.6% during the first quarter. Regal Partners Ltd now owns 5,193,688 shares of the company's stock worth $17,710,000 after purchasing an additional 2,286,285 shares during the period. Institutional investors own 55.95% of the company's stock.</p>
<div class="lb-trans"><p>大型投资者最近对该公司的持仓进行了调整。EP Wealth Advisors LLC 在第一季度购买了 Opthea 的新股份，价值约 $34,000。OLD Mission Capital LLC 在第一季度将其在 Opthea 的持仓增加了 78.7%。OLD Mission Capital LLC 现在拥有 19,167 股该公司的股票，价值 $65,000，此前在该期间又购买了 8,439 股。Twin Lakes Capital Management LLC 在第一季度将其在 Opthea 的持仓增加了 67.4%。Twin Lakes Capital Management LLC 现在拥有 33,156 股该公司的股票，价值 $113,000，此前在该期间又购买了 13,350 股。最后，Regal Partners Ltd 在第一季度将其在 Opthea 的持仓增加了 78.6%。Regal Partners Ltd 现在拥有 5,193,688 股该公司的股票，价值 $17,710,000，此前在该期间又购买了 2,286,285 股。机构投资者持有该公司 55.95% 的股票。</p>
</div><h2>About Opthea</h2>
<div class="lb-trans"><h2>关于 Opthea</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage.</p>
<div class="lb-trans"><p>Opthea Limited 是一家临床阶段的生物制药公司，专注于在澳大利亚开发和商业化主要用于眼病的治疗。该公司的开发活动基于涵盖血管内皮生长因子 (VEGF) VEGF-C、VEGF-D 和 VEGF 受体-3 的知识产权组合，用于治疗与血管和淋巴管生长以及血管渗漏相关的疾病。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Opthea</li>
<li>How to Buy Gold Stock and Invest in Gold</li>
<li>Rayonier-PotlatchDeltic Merger Signals Industry Upside</li>
<li>Why Are These Companies Considered Blue Chips?</li>
<li>Hims &amp; Hers Short Interest Nears All-Time High, Buy The Dip?</li>
<li>How to Calculate Options Profits</li>
<li>This Defense Stock Has a $57B Backlog and New AI Tailwinds</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票比 Opthea 更好</li>
<li>如何购买黄金股票并投资黄金</li>
<li>Rayonier-PotlatchDeltic 合并预示行业上行</li>
<li>为什么这些公司被视为蓝筹股？</li>
<li>Hims &amp; Hers 空头头寸接近历史高点，是否应该买入？</li>
<li>如何计算期权利润</li>
<li>这只防御性股票有 $570 亿的订单积压和新的 AI 发展机遇</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒是由叙述科学技术和 MarketBeat 的金融数据生成的，旨在为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送邮件至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Opthea Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 $1,000 在 Opthea 吗？</h2>
</div><p>Before you consider Opthea, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Opthea 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Opthea wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前买入……而 Opthea 并不在名单上。</p>
</div><p>While Opthea currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Opthea 目前在分析师中获得了 &#34;持有&#34; 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Opthea（NASDAQ:OPT）股价上涨 7.2% - 以下是原因